Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Evaluate crypto assets based on use case, supply dynamics, and market liquidity to guide beginner-friendly buying decisions for 2024.
26,888 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Caterpillar has emerged as a heavyweight in the Dow, powered by AI-driven infrastructure demand and mining activity. ...
As Royal Gold prepares to share Q4 2025 results, investors should focus on streaming contracts, cash flow, and balanc...
In late 2025, Berkshire added 8 million shares to a major energy producer, lifting its portfolio weight. This move po...
Oracle stunned traders with a solid earnings beat and optimistic long-term guidance, fueling a surge in after-hours a...
When a prominent executive questions a public pledge with a personal twist, investors and workers feel the reverberat...
Biotech stocks often ride a volatile wave of news, milestones, and insider moves. In the last year, one biotechnology...
Orion (OESX) 2026 earnings reveal a company navigating growth opportunities and profitability challenges. This deep d...
EEM’s 0.69% fee quietly drags down returns for investors, especially over decades. A cheaper alternative, IEMG at 0.0...
Oklo is developing compact nuclear reactors geared for AI data centers. This article lays out a grounded five-year ro...
Momentum can tilt a portfolio toward recent winners. This article explains how two Vanguard ETFs using momentum aim t...
Barings BDC (BBDC) fans the flames of income investing with a steady cash-flow model. As barings (bbdc) 2025 earnings...